Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 6/20 | 0.63 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSH | P09668 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7291267 | 0.87 | CTSB (0.49) | CTSBNPC1RAB9ACTRB1 | |
| SCHEMBL29910660 | 0.87 | CTSB (0.52) | CTSB | |
| Hydrochloric Acid SCHEMBL8878738 | 0.86 | CTSB (0.48) | CTSBNPC1RAB9ACTRB1 | |
| SCHEMBL24444411 | 0.84 | CTSB (0.64) | CTSBCAPN1NPC1RAB9ACTSL | |
| SCHEMBL20204691 | 0.84 | CTSC (0.58) | CTSBCAPN1CTSL | |
| SCHEMBL20204693 | 0.84 | CTSC (0.58) | CTSBCAPN1CTSL | |
| SCHEMBL8260887 | 0.83 | CTSB (0.65) | CTSBCAPN1CTSK | |
| SCHEMBL3487670 | 0.83 | CTSB (0.65) | CTSBCAPN1CTSK | |
| SCHEMBL7361627 | 0.83 | CTSB (0.52) | CTSBCAPN1CTSLCTSHCTSK | |
| SCHEMBL16566017 | 0.82 | CTSB (0.55) | CTSBCAPN1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1638579-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2006-03-29 | — | — | EP | claimed |
| WO-2005003150-A2 | COMPOSITIONS AND METHODS FOR USE OF A PROTEASE INHIBITOR AND ADENOSINE FOR PREVENTING ORGAN ISCHEMIA AND REPERFUSION INJURY | EMORY UNIVERSITY (US) | 2005-01-13 | — | — | WO | claimed |
| US-11124498-B2 | Compositions and methods for modulating protease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200048227-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-13 | — | — | US | disclosed |
| WO-2018097999-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124498-B2 | Compositions and methods for modulating protease activity | RNASE1, ADAM8, CTRL | CTSB 8/4885CAPN1 81/4885NPC1 1337/4885 |
| US-20200048227-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | RNASE1, ADAM8, CTRL | CTSB 8/4885CAPN1 81/4885NPC1 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.